about
Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis.A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@en
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@nl
type
label
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@en
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@nl
prefLabel
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@en
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@nl
P2093
P2860
P356
P1476
NGcGM3/VSSP vaccine as treatment for melanoma patients.
@en
P2093
Adriana Carr
Julio Hernández
Kirenia Pérez
Luis Enrique Fernández
Marta Osorio
P2860
P304
P356
10.4161/HV.24115
P577
2013-02-26T00:00:00Z